{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:44:51Z","timestamp":1783421091785,"version":"3.54.6"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.clon.2012.11.004","type":"journal-article","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T00:45:55Z","timestamp":1354754755000},"page":"217-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Skeletal-related Events and Clinical Outcomes in Patients with Bone Metastases and Normal Levels of Osteolysis: Exploratory Analyses"],"prefix":"10.1016","volume":"25","author":[{"given":"A.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl.","key":"10.1016\/j.clon.2012.11.004_bib1","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2012.11.004_bib2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1677\/ERC-09-0012","article-title":"Mechanisms of bone metastases of breast cancer","volume":"16","author":"Suva","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clon.2012.11.004_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3816\/SCT.2006.n.012","article-title":"Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases","volume":"3","author":"Costa","year":"2006","journal-title":"Support Cancer Ther"},{"key":"10.1016\/j.clon.2012.11.004_bib4","first-page":"341","article-title":"Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice","volume":"4","author":"Delea","year":"2006","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.clon.2012.11.004_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/01243894-200607000-00012","article-title":"Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer","volume":"1","author":"Delea","year":"2006","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2012.11.004_bib6","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer","volume":"14","author":"Lage","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clon.2012.11.004_bib7","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2012.11.004_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2012.11.004_bib9","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2012.11.004_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/ctrv.2000.0212","article-title":"Bone markers in the management of metastatic bone disease","volume":"27","author":"Lipton","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clon.2012.11.004_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2012.11.004_bib12","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.clon.2012.11.004_bib13","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2012.11.004_bib14","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial \u2014 the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2012.11.004_bib15","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A\u00a0randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2012.11.004_bib16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2012.11.004_bib17","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1053\/meta.2002.33344","article-title":"Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients","volume":"51","author":"Fukumitsu","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.clon.2012.11.004_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9343(96)00387-7","article-title":"Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density","volume":"102","author":"Chesnut","year":"1997","journal-title":"Am J Med"},{"issue":"Suppl. 3","key":"10.1016\/j.clon.2012.11.004_bib19","first-page":"iii124","article-title":"Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma: analysis of patients at high risk for skeletal complications","volume":"15","author":"Conte","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2012.11.004_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ctrv.2008.05.001","article-title":"Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clon.2012.11.004_bib21","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","article-title":"Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity","volume":"12","author":"Lipton","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clon.2012.11.004_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-008-0085-3","article-title":"Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in\u00a0vivo model","volume":"116","author":"Eck","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2012.11.004_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1359\/jbmr.2003.18.5.859","article-title":"The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation","volume":"18","author":"Garnero","year":"2003","journal-title":"J\u00a0Bone Miner Res"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655512003585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655512003585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:38:06Z","timestamp":1760542686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655512003585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0936655512003585"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2012.11.004","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skeletal-related Events and Clinical Outcomes in Patients with Bone Metastases and Normal Levels of Osteolysis: Exploratory Analyses","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2012.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}